SII gets nod to develop jab against Omicron
New Delhi: India’s drug regulator on Friday approved Serum Institute of India’s proposal to manufacture a drug substance for new Covid vaccine against Omicron variant of coronavirus and carry out its testing and analysis, official sources said. The move assumes significance in view of the country reporting a rise in daily new Covid-19 cases which […]
New Delhi: India’s drug regulator on Friday approved Serum Institute of India’s proposal to manufacture a drug substance for new Covid vaccine against Omicron variant of coronavirus and carry out its testing and analysis, official sources said.
The move assumes significance in view of the country reporting a rise in daily new Covid-19 cases which include the Omicron variant.
Looking to undertake vaccine research against the Omicron variant, Director, Government and Regulatory Affairs at SII, Prakash Kumar Singh, recently had submitted an application to the Drugs Controller General of India (DCGI) for grant of permission to manufacture Drug substance of SARS-CoV-2 rS Protein (COVID-l9)Recombinant Spike Nanoparticle Vaccine (Omicron Variant) for examination test and analysis.
After the review of their application, DCGI has given permission to manufacture SARS-CoV-2 rS Drug Substance (Omicron Variant) for Examination, Test and Analysis (for SIIPL Hadapsar site), an official source.
Meanwhile, Maharashtra reported 8,067 new coronavirus cases, as much as 50 per cent more than the day before, and eight deaths on Friday, the Health Department said.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
